Literature DB >> 23124750

The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae.

Hye-Lim Kwag1, Hyoung Jin Kim, Don Yong Chang, Hong-Jin Kim.   

Abstract

Human papillomavirus (HPV) is the cause of most cases of cervical cancer. HPV type 58 (HPV58) is the second most frequent cause of cervical cancer and high-grade squamous intraepithelial lesions (HSIL) in Asia and South / Central America, respectively. However, there is no vaccine against HPV58, although there are commercially available vaccines against HPV16 and 18. In this study, we produced HPV58 L1 protein from Saccharomyces cerevisiae, and investigated its immunogenicity. We first determined the optimum period of culture for obtaining HPV58 L1. We found that a considerable portion of the HPV58 L1 resulting from 48 h culture cannot be recovered by purification, while the HPV58 L1 resulting from 144 h culture is recovered efficiently: the yield of HPV58 L1 finally recovered from 144 h culture was 2.3 times higher than that from 48 h culture, although the production level of L1 protein from 144 h culture was lower than that from 48 h culture. These results indicate that the proportion of functional L1 protein from 144 h-cultured cells is significantly higher than that of 48 h-cultured cells. The HPV58 L1 purified from the 144 h culture was correctly assembled into structures similar to naturally occurring HPV virions. Immunization with the HPV58 L1 efficiently elicited anti-HPV58 neutralizing antibodies and antigen-specific CD4+ and CD8+ T cell proliferations, without the need for adjuvant. Our findings provide a convenient method for obtaining substantial amounts of highly immunogenic HPV58 L1 from S. cerevisiae.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124750     DOI: 10.1007/s12275-012-2292-1

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  36 in total

Review 1.  Towards the preparative and large-scale precision manufacture of virus-like particles.

Authors:  Leonard K Pattenden; Anton P J Middelberg; Marcus Niebert; Daniel I Lipin
Journal:  Trends Biotechnol       Date:  2005-10       Impact factor: 19.536

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.

Authors:  Lysann Schädlich; Tilo Senger; Carsten J Kirschning; Martin Müller; Lutz Gissmann
Journal:  Vaccine       Date:  2009-01-25       Impact factor: 3.641

4.  Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.

Authors:  S Y Chan; H Delius; A L Halpern; H U Bernard
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae.

Authors:  Mi-Kyung Woo; Sook-Jin Hur; Suenie Park; Hong-Jin Kim
Journal:  J Microbiol Biotechnol       Date:  2007-10       Impact factor: 2.351

6.  Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae.

Authors:  Min-A Park; Hyoung Jin Kim; Hong-Jin Kim
Journal:  Protein Expr Purif       Date:  2008-02-15       Impact factor: 1.650

7.  Detection of human papillomavirus type 58 in polydactylous Bowen's disease on the fingers and toes of a woman - concurrent occurrence of invasive vulval and cervical carcinomas.

Authors:  Hiroyuki Hara; Ayano Honda; Hiroyuki Suzuki; Tetsutaro Sata; Toshihiko Matsukura
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

8.  Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice.

Authors:  Jianhua Sun; Xiaoming Song; Songhua Hu
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

9.  Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions.

Authors:  Michael J Conway; Samina Alam; Eric J Ryndock; Linda Cruz; Neil D Christensen; Richard B S Roden; Craig Meyers
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

10.  The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.

Authors:  Hyoung Jin Kim; Su Jeung Lim; Hye-Lim Kwag; Hong-Jin Kim
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more
  6 in total

1.  Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Authors:  Hee-Jung Lee; Jong Kwang Yoon; Yoonki Heo; Hansam Cho; Yeondong Cho; Yongdae Gwon; Kang Chang Kim; Jiwon Choi; Jae Sung Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

2.  Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

Authors:  Hansam Cho; Hee-Jung Lee; Yoon-Ki Heo; Yeondong Cho; Yong-Dae Gwon; Mi-Gyeong Kim; Ki Hoon Park; Yu-Kyoung Oh; Young Bong Kim
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

3.  The concentration of carbon source in the medium affects the quality of virus-like particles of human papillomavirus type 16 produced in Saccharomyces cerevisiae.

Authors:  Hyoung Jin Kim; Yingji Jin; Hong-Jin Kim
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

4.  EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge.

Authors:  Xiaowen Wang; Xiangqian Xiao; Miao Zhao; Wei Liu; Lin Pang; Xin Sun; Shan Cen; Burton B Yang; Yuming Huang; Wang Sheng; Yi Zeng
Journal:  BMC Res Notes       Date:  2016-01-25

5.  A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model.

Authors:  Fei Yin; Yajun Wang; Na Chen; Dunquan Jiang; Yefeng Qiu; Yan Wang; Mei Yan; Jianping Chen; Haijiang Zhang; Yongjiang Liu
Journal:  Papillomavirus Res       Date:  2017-03-01

Review 6.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.